Last Updated: 01/16/2024

Namita Chittoria, MD

University of Utah

School of Medicine

Oncology

CONTACT INFORMATION

Huntsman Cancer Institute

Medical Oncology

2000 Circle Of Hope, KFK

Salt Lake City, UT 84112

801-213-8473 (phone)

801-585-0124 (fax)

namita.chittoria@hci.utah.edu

EDUCATION

Years

Degree

Institution (Area of Study)

2012 - 2013

Fellow

Cleveland Clinic Foundation (Experimental Therapeutics)

Cleveland, OH

2010 - 2012

Fellow

University of Texas Health Science Center (Medical Oncology)

San Antonio, TX

2009 - 2010

Fellow

University at Buffalo (Palliative Medicine and Hospice)

Buffalo, NY

2006 - 2009

Resident

SUNY Upstate Medical University (Internal Medicine)

Syracuse, NY

2002 - 2005

Resident

King George’s Medical University (Internal Medicine)

Lucknow, India

1996 - 2001

M.B.B.S.

King George’s Medical University (Medicine)

Lucknow, India

BOARD CERTIFICATIONS

11/13/2013 - 12/31/2023

American Board of Internal Medicine (Sub: Medical Oncology), Certified

08/24/2009 - 12/31/2019

American Board of Internal Medicine

RESEARCH INTERESTS

Triple Negative Breast Cancer

UNIVERSITY OF UTAH ACADEMIC HISTORY

Internal Medicine (Oncology), 09/03/2019 - Present

09/03/2019 - Present

Assistant Professor (Clinical)

PROFESSIONAL EXPERIENCE

Full-Time Positions

2019 - Present

Assistant Profesor, University of Utah, Salt Lake City, UT

2017 - 2019

Medical Oncologist, Intermountain Health Care, McKay Dee Hospital, Layton Hospital & Ogden, UT

2013 - 2017

Assistant Professor, SUNY Upstate Medical University, Syracuse, NY

Responsibilities:
• Breast Cancer clinic and inpatient consults (11/2014 – 06/2016)
• Teaching and supervision of fellows, residents and medical students

2013 - 2017

Staff Physician, Cancer Center, Syracuse VA Medical Center, Syracuse, NY

Responsibilities:
• Outpatient continuity clinics (emphasizing GU malignancies) and inpatient consults
• Lead Oncology research program
- VA Site Principal Investigator for Alliance in Clinical Trials for Oncology

HONORS AND AWARDS

2013

Merit Award, American Society of Clinical Oncology Annual Meeting, Chicago, IL

2012

Chosen to be a participant, ASCO/AACR Workshop: Methods in Clinical Cancer Research, Vail, CO

SERVICE AT PREVIOUS INSTITUTIONS

2013 - 2017

Member, Syracuse VA Medical Center, GU and Thoracic Tumor Board, held every 2 weeks

2013 - 2017

Member, Syracuse VA Medical Center, Transfusion Committee, to oversee safety, AAAB compliance, appropriateness and accessibility of blood product support

2013 - 2017

Member, Syracuse VA Medical Center, Cancer Committee, to oversee integrated activities of Pharmacy, Palliative Care, Nursing, Pain Management, Women’s Health, Quality Control, Radiation Oncology, and Research activities

ADDITIONAL SERVICE CONTRIBUTIONS

2023 - Present

Gilead Science Advisory Board

2022 - Present

ImpediMed Oncology Advisory Board  

FUNDING

Past Contracts

10/19/16 - 07/30/18

SWOG S1416 A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.  

Principal Investigator(s): Namita Chittoria

Role: Principal Investigator

09/08/20 - 07/27/21

CytoDyne

Principal Investigator(s): Namita Chittoria

Role: Principal Investigator

08/25/17 - 03/29/21

Alliance Foundation AFT-38 PATINA        

Principal Investigator(s): Namita Chittoria

Role: Principal Investigator

CLINICAL STUDIES

2023 - Present

Randomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

2022 - Present

Phase II, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer.

2020 - Present

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.  

2020 - Present

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

TEACHING RESPONSIBILITIES/ASSIGNMENTS

Mentoring/Advising

Fellow

2013 - 2016

Member, Research Committee, SUNY Upstate Medical University, for fellows in training (mentor of two fellows)

PEER-REVIEWED JOURNAL ARTICLES

1.

Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol, 221(2), 228-239.

2.

Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urol Oncol, 2019 Jun;37((6)), 352.e19-352.e24..

3.

Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E (2016). Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer, 16, 254.

4.

Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee J-L, Srinivas S, Knox JK, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of Patients with Metastatic Sarcomatoid Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, Apr13((2)), e79-85.

5.

Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, 13(2), e79-85.

6.

Miraj R, Chittoria N, Mehta P, Murthy U (2007). Heat Stress and Exercise-Induced Ischemic Colitis in a 21 Year Old. Am J Gastroenterol, (S2), s351.

OTHER PUBLICATIONS

Case Reports

1.

Basnet A, Khullar G, Mehta R, Chittoria N (2017). A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab. Clin Genitourin Cancer, 15(5), e881-e884.

Pedagogical Publications

1.

Chittoria N, Rini BI (2012). Renal Cell Carcinoma [Web], Cleveland, OH: The Disease Management Project, Carey WD (eds). Available: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/.

PUBLISHED ABSTRACTS

1.

Cristofanilli M, Chittoria N, Ehsani S, Rui H, Dolezal M, Stork-Sloots L, de Snoo F, Recknor C, Abramson V (2022).

A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC) Abstract P5-17-08

[Abstract]., 84(4_suppl).

2.

Rini BI, Wood LS, Elson P, Zhu H, Chittoria N, Mittal K, Dreicer R, Gilligan TD, Shah SN, Garcia JA (2013). A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 31 (15_suppl), 4515.

3.

Rajan A, Tolocica I, El-Zammar O, Chittoria N, Singh M, Newman N, Gajra A (2008). mTOR Expression in Pancreatic Adenocarcinoma and its Correlation with Survival [Abstract]. J Clin Oncol , (20 suppl), 22169.